GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Beta

Cerevel Therapeutics Holdings (STU:673) Beta : N/A (As of May. 12, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-12), Cerevel Therapeutics Holdings's Beta is Not available.


Cerevel Therapeutics Holdings Beta Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Beta Chart

Cerevel Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beta
- - - - -

Cerevel Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cerevel Therapeutics Holdings's Beta

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerevel Therapeutics Holdings's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's Beta falls into.



Cerevel Therapeutics Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Cerevel Therapeutics Holdings  (STU:673) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cerevel Therapeutics Holdings Beta Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerevel Therapeutics Holdings (STU:673) Business Description

Traded in Other Exchanges
Address
222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines